Acoramidis ATTR Cm denied as non-formulary by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Acoramidis as Non-Formulary for ATTR-CM — and How to Appeal

A non-formulary denial means acoramidis is not included on Aetna's standard drug formulary for your plan, or is placed at a tier that your plan does not cover without an exception. Non-formulary denials are appealable — plans are required to have a formulary exception process, and for a disease like ATTR-CM where acoramidis may be the most appropriate or only clinically suitable agent, that process can succeed.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review. Additionally, formulary exception requests — separate from but often paired with a formal appeal — require the insurer to consider coverage when a covered drug at the applicable tier is not clinically appropriate for the member. If the internal process fails, independent external review is available within approximately four months of the final internal denial.

## Your Appeal Timeline

• Formulary exception request: File this first or simultaneously with the internal appeal — it is often the faster pathway.
• Internal appeal deadline: Typically 180 days from the denial notice (confirm on your Explanation of Benefits).
• External review: Within approximately four months of final internal denial.
• Expedited review: Request this track if the patient's condition is urgent; ATTR-CM is a progressive condition that may meet the urgency threshold.

## Documentation to Gather

1. Confirmed ATTR-CM diagnosis: Chart documentation of the diagnosis, including subtype and disease staging. 2. Formulary alternatives considered and why they are inadequate: For each drug that Aetna's formulary offers as an alternative in this therapeutic area, your cardiologist should document why it is not clinically appropriate for this patient — whether due to mechanism, indication, tolerability, or other clinical factors. 3. Prescriber medical-necessity letter for the exception: A letter stating that no covered formulary alternative is clinically appropriate, that acoramidis is the appropriate agent, and the clinical basis for that conclusion. 4. FDA-approved indication: Confirm that the use being requested matches the FDA-approved indication for acoramidis, as this supports the argument that it is a standard-of-care therapy. 5. Applicable guideline reference: Note alignment with ACC/AHA or relevant amyloidosis society guidance on ATTR-CM treatment.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria (available in your plan documents or by calling member services). Map each requirement to available evidence:

| Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative is clinically inappropriate | [Prescriber letter addressing each alternative] | | Confirmed diagnosis in the approved indication | [Chart diagnosis documentation] | | Medical necessity for acoramidis specifically | [Cardiologist letter with rationale] | | Standard-of-care support | [Guideline organization reference] |

Formulary exception appeals are often resolved faster than standard appeals — pursue both tracks in parallel where possible.